Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1). - Santoni M; Roviello G; Grande E; De Giorgi U; Fiala O; Seront E; Molina-Cerrillo J; Pichler R; Myint ZW; Kucharz J; Kanesvaran R; Büttner T; et al. (Cancer immunology, immunotherapy : CII, 2025)